S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
NASDAQ:PNT

POINT Biopharma Global (PNT) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$12.49
$12.51
50-Day Range
$12.45
$14.23
52-Week Range
$6.57
$14.35
Volume
3.29 million shs
Average Volume
1.44 million shs
Market Capitalization
$1.33 billion
P/E Ratio
13.89
Dividend Yield
N/A
Price Target
$12.80

POINT Biopharma Global MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
2.4% Upside
$12.80 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.69) to ($0.68) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.17 out of 5 stars

Medical Sector

918th out of 939 stocks

Pharmaceutical Preparations Industry

419th out of 429 stocks

PNT stock logo

About POINT Biopharma Global Stock (NASDAQ:PNT)

POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.

PNT Stock News Headlines

Lilly Completes Acquisition of POINT Biopharma
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Piper Sandler Keeps Their Hold Rating on POINT Biopharma Global (PNT)
Recap: POINT Biopharma Global Q3 Earnings
Lilly Extends Tender Offer For POINT Biopharma Global Until Nov. 16
See More Headlines
Receive PNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for POINT Biopharma Global and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PNT
Fax
N/A
Employees
129
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.80
High Stock Price Target
$14.00
Low Stock Price Target
$12.50
Potential Upside/Downside
+2.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
10 Analysts

Profitability

Net Income
$98.29 million
Pretax Margin
52.16%

Debt

Sales & Book Value

Annual Sales
$226.58 million
Cash Flow
$0.94 per share
Book Value
$4.68 per share

Miscellaneous

Free Float
89,518,000
Market Cap
$1.33 billion
Optionable
Optionable
Beta
N/A
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Allan Charles Silber (Age 73)
    Executive Chairman
    Comp: $1.02M
  • Dr. Joe A. McCann Ph.D. (Age 45)
    CEO & Director
    Comp: $1.06M
  • Dr. Neil E. Fleshner FRCSC (Age 59)
    M.D., M.PH, Chief Medical Officer & Director
    Comp: $318.49k
  • Ms. Jessica D. Jensen M.P.H. (Age 43)
    Executive Vice President of Clinical Development
    Comp: $816.17k
  • Mr. Bill Demers B.B.A. (Age 64)
    F.C.A., FCPA, CFO & Corporate Secretary
    Comp: $78.26k
  • Ms. Justyna Kelly M.Sc. (Age 38)
    Chief Operating Officer
  • Ms. Jazz Braich
    SVP of People & Culture
  • Mr. Ari Shomair
    VP of Corporate Affairs & Chief of Staff
  • Dr. Myra Rosario Herle Ph.D.
    R.Ph., Executive Vice President of Regulatory Affairs
  • Dr. Matthew P. Vincent J.D.
    Ph.D., Senior Vice President of Business Development

PNT Stock Analysis - Frequently Asked Questions

Should I buy or sell POINT Biopharma Global stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for POINT Biopharma Global in the last twelve months. There are currently 10 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PNT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PNT, but not buy additional shares or sell existing shares.
View PNT analyst ratings
or view top-rated stocks.

What is POINT Biopharma Global's stock price target for 2024?

10 brokerages have issued 12-month price objectives for POINT Biopharma Global's stock. Their PNT share price targets range from $12.50 to $14.00. On average, they expect the company's stock price to reach $12.80 in the next year. This suggests a possible upside of 2.4% from the stock's current price.
View analysts price targets for PNT
or view top-rated stocks among Wall Street analysts.

How were POINT Biopharma Global's earnings last quarter?

POINT Biopharma Global Inc. (NASDAQ:PNT) announced its quarterly earnings results on Monday, November, 13th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.07. The company earned $2.79 million during the quarter, compared to the consensus estimate of $8 million. POINT Biopharma Global had a trailing twelve-month return on equity of 21.10% and a net margin of 39.62%.

Who are POINT Biopharma Global's major shareholders?

POINT Biopharma Global's stock is owned by many different retail and institutional investors. Top institutional shareholders include Clear Street Markets LLC (0.00%), Perceptive Advisors LLC (0.00%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Allan C Silber, Bvf Partners L P/Il, Joe A Mccann, Jonathan R Goodman, Neil E Fleshner and Yael Margolin.
View institutional ownership trends
.

This page (NASDAQ:PNT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners